or Try an Advanced Search...

    Technical Analysis for ADVM - Adverum Biotechnologies, Inc.

    Grade Last Price % Change Price Change
    F 6.97 1.60% 0.11
    ADVM closed up 1.6 percent on Monday, July 1, 2024, on approximately normal volume. The price action carved out a bullish hammer (or hammer-like) candlestick pattern. That may indicate an upside reversal. Look for price to trade above the high of the hammer for confirmation.
    4 Watchers
    Watchlist Portfolio

    Trend Table & Recent EOD Trading Signals

    ADX Long Term Intermediate Term Short Term
    Weak or Absent Down Down Up
    Historical ADVM trend table...
    Date Alert Name Type % Chg
    Hammer Candlestick Bullish 0.00%
    Doji - Bullish? Reversal 0.00%
    Volume Surge Other 1.60%
    20 DMA Resistance Bearish -0.14%
    Shooting Star Candlestick Bearish -0.14%
    Doji - Bearish? Reversal -0.14%
    Up 3 Days in a Row Strength -0.14%
    Up 4 Days in a Row Strength -0.14%
    Pocket Pivot Bullish Swing Setup 0.87%
    Gapped Up Strength 0.87%
    Older End-of-Day Signals for ADVM ...

       Recent Intraday Alerts

    Alert Time
    Fell Below Previous Day's Low about 6 hours ago
    Down 3% about 6 hours ago
    Possible Inside Day about 6 hours ago
    Down 2 % about 7 hours ago
    Down 1% about 10 hours ago
    View Earlier Intraday Alerts

    Get a Trading Assistant

    Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
    Track My Stocks
    Configure default chart indicators
    ADVM Chart by TradingView
    Basic chart:

    Profile

    Adverum Biotechnologies, Inc. Description

    Adverum Biotechnologies, Inc., a gene therapy company, engages in discovering and developing novel medicines that offer therapeutic benefit to patients suffering from chronic or debilitating disease. It primary focuses on developing AVA-101, which is in a Phase IIa trial for the treatment of wet age-related macular degeneration (AMD). The company is also developing AVA-201, a product candidate for the prevention of wet AMD; AVA-311 that is in preclinical studies for the treatment of juvenile X-linked retinoschisis, a rare genetic disease of the retina with no approved therapy; and AVA-322 and AVA-323 for the treatment of color vision deficiency. Avalanche Biotechnologies, Inc. has a collaboration agreement with Regeneron Pharmaceuticals, Inc. to research, develop, and commercialize gene therapy products. The company was formerly known as Avalanche Biotechnologies, Inc. and changed its name to Adverum Biotechnologies, Inc. in May 2016. Adverum Biotechnologies, Inc. was founded in 2006 and is headquartered in Menlo Park, California.

    Classification
    Sector: Healthcare
    Industry: Biotechnology
    Keywords: Disease Gene Therapy Macular Degeneration Genetic Diseases Retina Wet Age Related Macular Degeneration Rare Genetic Disease Gene Therapy Products Regeneron Adverum Biotechnologies Gene Therapy Of The Human Retina

    Is ADVM a Buy, Sell or Hold?

    Indicator Bull Case Neutral / Hold Bear Case
    50 DMA
    200 DMA
    ADX Trend
    Oversold / Overbought
    Relative Strength
    Counts: 0 bullish, 3 bearish and 2 neutral indicators. You may wish to incorporate that into your trading strategies.

    Recent News

    Date Title
    Jun 18 Adverum Biotechnologies to Participate in TD Cowen’s Genetic Medicines & RNA Summit
    Jun 11 Adverum Biotechnologies Announces Appointments of Dr. Rabia Gurses Ozden as Chief Medical Officer and Dr. Szilárd Kiss as a Member of the Board of Directors
    May 10 Adverum Biotechnologies Reports Q1 2024 Results: A Detailed Look at Financials and Pipeline Progress
    May 10 Down -19.72% in 4 Weeks, Here's Why You Should You Buy the Dip in Adverum Biotechnologies (ADVM)
    May 9 Adverum Biotechnologies GAAP EPS of -$1.50
    May 9 Adverum Biotechnologies Reports First Quarter 2024 Financial Results and Provides Pipeline Highlights
    May 9 Are Medical Stocks Lagging Ligand Pharmaceuticals (LGND) This Year?
    May 3 Adverum Biotechnologies to Participate in Upcoming May Investor Conferences
    May 2 Adverum Biotechnologies (ADVM) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
    May 1 Adverum Biotechnologies a new buy at H.C. Wainwright on wet AMD gene therapy
    See more ADVM news...

    Comments

    View full discussion...

    Indicators

    Indicator Value
    52 Week High 29.7
    52 Week Low 6.38
    Average Volume 385,066
    200-Day Moving Average 11.43
    50-Day Moving Average 8.41
    20-Day Moving Average 7.24
    10-Day Moving Average 6.87
    Average True Range 0.50
    RSI (14) 38.27
    ADX 19.61
    +DI 18.61
    -DI 25.17
    Chandelier Exit (Long, 3 ATRs) 6.84
    Chandelier Exit (Short, 3 ATRs) 7.89
    Upper Bollinger Bands 8.09
    Lower Bollinger Band 6.39
    Percent B (%b) 0.34
    BandWidth 23.51
    MACD Line -0.48
    MACD Signal Line -0.56
    MACD Histogram 0.08
    Fundamentals Value
    Market Cap 704.16 Million
    Num Shares 101 Million
    EPS -1.26
    Price-to-Earnings (P/E) Ratio -5.53
    Price-to-Sales 62.39
    Price-to-Book 1.70
    PEG Ratio 0.00
    Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
    Resistance 4 (R4) 7.60
    Resistance 3 (R3) 7.54 7.27 7.50
    Resistance 2 (R2) 7.27 7.11 7.30 7.46
    Resistance 1 (R1) 7.12 7.01 6.99 7.18 7.42
    Pivot Point 6.85 6.85 6.78 6.88 6.85
    Support 1 (S1) 6.70 6.69 6.57 6.76 6.52
    Support 2 (S2) 6.43 6.59 6.46 6.48
    Support 3 (S3) 6.28 6.43 6.45
    Support 4 (S4) 6.34